A prospective comparative interventional study of intravenous labetalol and oral nifedipine in the management of severe preeclampsia at a tertiary care hospital
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262127Keywords:
Acute severe hypertension, Labetalol, Nifedipine, Maternal outcome, Perinatal outcome, Pregnancy, Severe preeclampsiaAbstract
Background: Severe preeclampsia is an obstetric emergency requiring prompt blood pressure control to prevent maternal and perinatal morbidity. Intravenous labetalol and oral nifedipine are both recommended first-line agents, yet comparative data from Indian tertiary care settings remain limited.
Methods: A hospital-based prospective non-randomized comparative interventional study was conducted at the Department of Obstetrics and Gynecology, Government Medical College, Akola, Maharashtra. One hundred and fifty women with severe preeclampsia were allocated equally to intravenous labetalol (Group A, n=75) or oral nifedipine (Group B, n=75) per treating-unit protocol from November 2022 to October 2023. Blood pressure was recorded at baseline, 30 minutes, 1 hour, 2 hours, 6 hours and 24 hours. Maternal complications and perinatal outcomes were compared.
Results: Both agents produced progressive, clinically meaningful reductions in systolic and diastolic blood pressure. Systolic blood pressure was lower in the nifedipine group at several time points, but baseline systolic pressure also differed between groups, requiring cautious interpretation. Maternal complication rates were comparable (no complication: labetalol 74.7% vs. nifedipine 72.0%; p=0.287). Birth-weight distribution was similar. Five-minute Apgar scores and NICU admission rates differed significantly in favour of nifedipine (p=0.043 each), though absolute event numbers were small.
Conclusions: Intravenous labetalol and oral nifedipine were both effective first-line options for acute blood pressure control in severe preeclampsia. Oral nifedipine offers practical advantages when IV access is limited. IV labetalol remains valuable when titratable parenteral therapy is preferred. Prompt protocol-based treatment is more important than rigid preference for either drug.
References
World Health Organization. WHO recommendations: drug treatment for severe hypertension in pregnancy. Geneva: WHO. 2018. Available at: https://www.who.int/publications. Accessed on 21 August 2025.
Mammaro A, Carrara S, Cavaliere A, Ermito S, Dinatale A, Pappalardo EM, et al. Hypertensive disorders of pregnancy. J Prenat Med. 2009;3(1):1-5.
Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia: pathophysiology and clinical presentations. J Am Coll Cardiol. 2020;76(14):1690-702.
Montgomery AL, Ram U, Kumar R, Jha P. Million Death Study Collaborators. Maternal mortality in India: causes and healthcare service use based on a nationally representative survey. PLoS One. 2014;9(1):83331.
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2):21-41.
Frishman WH. Properties of labetalol, a combined alpha- and beta-blocking agent. Cardiovasc Drugs Ther. 1988;2(3):343-53.
MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193-219.
Vermillion ST, Scardo JA, Newman RB, Chauhan SP. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181(4):858-61.
Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119(1):78-85.
Shekhar S, Sharma C, Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol. 2013;122(5):1057-63.
Zulfeen M, Tatapudi R, Sowjanya R. IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2019;236:46-52.
Easterling T, Mundle S, Bracken H, Magee L, Mittal S, Nanda D, et al. Oral antihypertensive regimens (nifedipine retard, labetalol and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394(10203):1011-21.
Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016;123(1):40-7.
Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10(10):2252.
Nivethana KB, Priya SS, Karunanithi K. A comparative study of IV labetalol with oral nifedipine in severe preeclampsia. Int J Clin Obstet Gynaecol. 2020;4(1):388-92.
Downloads
Published
How to Cite
Issue
Section
